Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
14 nov. 2023 06h30 HE
|
Affimed N.V.
Acimtamig (also known as AFM13) combination with AlloNK® (also known as AB-101): Initiated LuminICE-203. Company on track to report initial data in H1 2024.Acimtamig: Received fast-track designation...
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
09 nov. 2023 06h30 HE
|
Affimed N.V.
MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
07 nov. 2023 06h30 HE
|
Affimed N.V.
MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
03 nov. 2023 12h05 HE
|
Affimed N.V.
Addition of Affimed’s innate cell engager (ICE®) improves cytotoxicity of natural killer (NK) cells and CAR-NK cellsNK cells with ICE® show at least comparable anti-tumor cell efficacy to CAR-NK cells...
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
02 nov. 2023 09h05 HE
|
Affimed N.V.
In 36 patients with CD30-positive lymphoma treated at the recommended Phase 2 dose level (RP2D), the combination treatment of AFM13 with allogeneic NK cells shows a 94.4% objective response rate and a...
Affimed to Participate in Upcoming Investor Conferences
01 nov. 2023 06h30 HE
|
Affimed N.V.
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...
Affimed Announces Listing Transfer to Nasdaq Capital Markets
04 oct. 2023 06h30 HE
|
Affimed N.V.
MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
27 sept. 2023 09h05 HE
|
Affimed N.V.
MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed to Present at the Cantor Global Healthcare Conference 2023
21 sept. 2023 06h30 HE
|
Affimed N.V.
MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
12 sept. 2023 06h30 HE
|
Affimed N.V.
AFM13 in combination with AlloNK® (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the...